NCT03932786Recruiting
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Research Into Visual Endpoints and RB Health Outcomes After Treatment (RIVERBOAT)
Source: ClinicalTrials.gov · Last updated 19 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 900 (estimated)
- First submitted
- 15 Mar 2019
- Start date
- 24 Jan 2019
- Primary completion date
- Jan 2030
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT03932786
What you commit to
- Study type: Observational
- Planned participants: 900
- From 24 Jan 2019 to the primary completion date, Jan 2030
- 11 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Unilateral or bilateral intraocular retinoblastoma
- Diagnosis between the ages of 0 - 17.99 years
- Diagnosis on or after January 1, 2008
- No exclusions based on primary or secondary treatment modalities
- Retrospective group patients must be ≥ 6 months post end of treatment at study entry
- For those already at this timepoint, they are now eligible
- For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are ≥ 6 months post end of treatment
- Prospective group patients must not have begun treatment
- Patients with diminished capacity will not be enrolled.
- Language: Patients must be able to communicate in English, French, or Spanish
- Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient.
- Regulatory Requirements: All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.
Sex: All · Accepts healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Hosptial for Sick Children Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| University of Illinois Chicago Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| Lurie Children's Hospital Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Recruiting |
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Texas Childeren's Hospital Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Children's Hospital of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
| University of Minnesoa Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
| Vanderbilt-Ingram Cancer Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Washington School of Medicine at St. Louis Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.